<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pentoxifylline: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pentoxifylline: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pentoxifylline: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9757" href="/d/html/9757.html" rel="external">see "Pentoxifylline: Drug information"</a> and <a class="drug drug_patient" data-topicid="10965" href="/d/html/10965.html" rel="external">see "Pentoxifylline: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F1054849"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Blood Viscosity Reducer Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812544"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bbf59dd9-a63d-4bd2-bca3-751819171cea">Kawasaki disease; adjunctive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Kawasaki disease; adjunctive:</b> Limited data available, efficacy results variable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8929744']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8929744'])">Ref</a></span>); AHA recommendations do not address pentoxifylline for the treatment of Kawasaki disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28356445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28356445'])">Ref</a></span>): Infants ≥2 months and Children: Oral: 20 mg/kg/day in 3 divided doses in combination with standard IV immunoglobulin and aspirin therapy; specific role in disease management undefined; data suggests use in patients with high serum concentrations of TNF may be appropriate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24944359','lexi-content-ref-7957426']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24944359','lexi-content-ref-7957426'])">Ref</a></span>); the initial trial (n=22, mean age: 2 years, youngest: 6 months) reported a lower incidence of coronary artery lesions in patient receiving pentoxifylline compared to those who did not; all patients received aspirin and IV gamma globulin therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7957426']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7957426'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F52729809"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Use with caution; monitor for enhanced therapeutic and toxic effects; <b>Note:</b> Pentoxifylline is not eliminated unchanged in the urine; however, the pharmacologically active metabolite (M-V) is; M-V may accumulate in patients with renal impairment and add to pharmacologic and toxic effects. Based on experience in adult patients, dosing adjustment suggested.</p></div>
<div class="block dohp drugH1Div" id="F52729810"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; use with caution.</p></div>
<div class="block doa drugH1Div" id="F208255"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9757" href="/d/html/9757.html" rel="external">see "Pentoxifylline: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2e850078-b62e-4303-98c0-fc362652a111">Intermittent claudication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intermittent claudication:</b>
<b>Oral:</b> 400 mg 3 times daily; maximal therapeutic benefit may take 2 to 4 weeks to develop; recommended to maintain therapy for at least 8 weeks. May reduce to 400 mg twice daily if GI or CNS side effects occur; discontinue if side effects persist.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use for the treatment of intermittent claudication refractory to exercise therapy (and smoking cessation) has been discouraged by The American College of Chest Physicians (ACCP) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Guyatt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Guyatt.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b1ee1b61-2217-4323-89ba-9980254a0036">Venous leg ulcer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Venous leg ulcer (off-label use):</b>
<b>Oral:</b> 400 mg 3 times daily (with compression therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23235582','lexi-content-ref-17199831']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23235582','lexi-content-ref-17199831'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991646"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function </b>(expert opinion derived from Aronoff 2007 and Paap 1996):</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥60 mL/minute: <b>Oral:</b> No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to &lt;60 mL/minute: <b>Oral:</b> 400 mg twice daily; however, doses up to 1.2 g/day have been reasonably well-tolerated in patients with stage III and IV chronic kidney disease (CKD) (CrCl 15 to 60 mL/minute) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24970885']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24970885'])">Ref</a></span>); therefore, increasing the dose to 400 mg 3 times daily may be considered in certain patients based on tolerability (the dose limiting effect is primarily GI intolerance) and potential benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: <b>Oral:</b> 400 mg once daily; however, doses up to 1.2 g/day have been reasonably well-tolerated in patients with stage III and IV CKD (CrCl 15 to 60 mL/minute) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24970885']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24970885'])">Ref</a></span>); therefore, increasing the dose up to 400 mg 2 or 3 times daily may be considered in certain patients with CrCl 15 to 30 mL/minute based on tolerability (the dose-limiting effect is primarily GI intolerance) and potential benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (pentoxifylline and metabolites [&gt;15%/hour]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3428162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3428162'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 400 mg once daily. When scheduled dose falls on a dialysis day, administer after dialysis. Supplemental postdialysis dosing not required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1','lexi-content-ref-8826548','lexi-content-ref-3428162','lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1','lexi-content-ref-8826548','lexi-content-ref-3428162','lexi-content-ref-expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b>
<b>Oral:</b> 400 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1','lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1','lexi-content-ref-expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b>
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) and minimal residual kidney function unless otherwise noted. Close monitoring of response and adverse reactions (eg, GI intolerance) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Pentoxifylline is likely to be somewhat cleared by CRRT; dose as for patients with CrCl 30 to &lt;60 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b>
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Close monitoring of response and adverse reactions (eg, GI intolerance) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Pentoxifylline is likely to be somewhat cleared by PIRRT; dose as for patients with CrCl 15 to 30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.dor'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988948"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, pentoxifylline exposure is increased with hepatic impairment; use with caution.</p></div>
<div class="block adr drugH1Div" id="F208222"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Gastrointestinal: Nausea (2%), vomiting (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylactic shock, anaphylactoid reaction, anaphylaxis, angioedema, angina pectoris, anorexia, anxiety, aplastic anemia, aseptic meningitis, bloating, blurred vision, cardiac arrhythmia, chest pain, cholecystitis, confusion, conjunctivitis, constipation, decreased serum fibrinogen, depression, dysgeusia, dyspnea, edema, epistaxis, eructation, flatulence, flu-like symptoms, hallucination, hepatitis, hypotension, increased liver enzymes, jaundice, laryngitis, leukemia, leukopenia, malaise, nail disease (brittle fingernails), nasal congestion, otalgia, pancytopenia, pruritus, purpura, scotoma, seizure, sialorrhea, skin rash, sore throat, tachycardia, thrombocytopenia, tremor, urticaria, weight changes, xerostomia</p></div>
<div class="block coi drugH1Div" id="F208235"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Patients previously exhibiting intolerance to pentoxifylline, xanthines (eg, caffeine, theophylline), or any component of the formulation; recent cerebral and/or retinal hemorrhage</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Acute MI, severe coronary artery disease when myocardial stimulation might prove harmful, peptic ulcers (current or recent)</p></div>
<div class="block war drugH1Div" id="F208219"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis/anaphylactoid reactions: Discontinue at first sign of anaphylaxis or anaphylactoid reaction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment; the bioavailability of pentoxifylline and metabolite I is increased. Has not been studied in patients with severe hepatic disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; bioavailability of active metabolite V may be increased.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly due to the potential for cardiac, hepatic, or renal impairment.</p></div>
<div class="block foc drugH1Div" id="F208229"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 400 mg</p></div>
<div class="block geq drugH1Div" id="F208215"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F208237"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (Pentoxifylline ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $1.14 - $1.50</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867900"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 400 mg</p></div>
<div class="block exp drugH1Div" id="F10806425"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">A 20 mg/mL oral suspension may be made using tablets. Crush ten 400 mg tablets and reduce to a fine powder. Add a small amount of purified water and mix to a uniform paste; mix while adding purified water to <b>almost</b> 200 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 200 mL. Label "shake well" and "refrigerate". Stable 91 days.</p>
<div class="reference">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>
</div>
<div class="block admp drugH1Div" id="F52613566"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with food or antacids to decrease GI upset. Do not crush, break, or chew extended or controlled release tablet, swallow whole.</p></div>
<div class="block adm drugH1Div" id="F208232"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with food. Swallow whole; do not chew, crush, or divide.</p>
<p style="text-indent:-2em;margin-left:2em;">Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. No alternative formulations are available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, if pentoxifylline extended release is continued, close clinical monitoring is advised in the immediate postoperative phase for the theoretical circumstance of reduced absorption after bariatric surgery.</p></div>
<div class="block sts drugH1Div" id="F554088"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store between 20°C to 25°C (68°F to 77°F); protect from light.</p></div>
<div class="block usep drugH1Div" id="F53568308"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of intermittent claudication on the basis of chronic occlusive arterial disease of the limbs (FDA approved in adults). <b>Note:</b> In adults, may improve function and symptoms, but not intended to replace more definitive therapy. <b>T</b>he American College of Chest Physicians (ACCP) discourages the use of pentoxifylline for the treatment of intermittent claudication refractory to exercise therapy (and smoking cessation) (Guyatt 2012). Has also been used as adjunct therapy for treatment of Kawasaki disease.</p></div>
<div class="block mst drugH1Div" id="F208304"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Pentoxifylline may be confused with tamoxifen</p>
<p style="text-indent:-2em;margin-left:4em;">Trental may be confused with Bentyl, Tegretol, Trandate</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F208290"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F208224"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Pentoxifylline may enhance the antiplatelet effect of Agents with Antiplatelet Properties. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: Pentoxifylline may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Pentoxifylline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Moderate): May increase the serum concentration of Pentoxifylline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Strong): May increase the serum concentration of Pentoxifylline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Pentoxifylline may enhance the anticoagulant effect of Heparin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparins (Low Molecular Weight): Pentoxifylline may enhance the anticoagulant effect of Heparins (Low Molecular Weight). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketorolac (Nasal): May enhance the adverse/toxic effect of Pentoxifylline. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketorolac (Systemic): May enhance the adverse/toxic effect of Pentoxifylline. Specifically, the risk of bleeding may be increased with this combination.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Pentoxifylline may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Pentoxifylline may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F208246"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food may decrease rate but not extent of absorption. Pentoxifylline peak serum levels may be decreased if taken with food.</p></div>
<div class="block dic drugH1Div" id="F208239"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May be taken with meals.</p></div>
<div class="block rep_considerations drugH1Div" id="F49321142"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Pentoxifylline may be used to test sperm viability when evaluating nonfertile males (ASRM 2015). It has also been evaluated for the treatment of infertility due to endometriosis, but use for this purpose is not currently recommended (Lu 2012).</p></div>
<div class="block pri drugH1Div" id="F208238"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events have been observed in animal reproduction studies.</p></div>
<div class="block pha drugH1Div" id="F208218"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Pentoxifylline increases blood flow to the affected microcirculation. Although the precise mechanism of action is not well-defined, blood viscosity is lowered, erythrocyte flexibility is increased, leukocyte deformability is increased, and neutrophil adhesion and activation are decreased. Overall, tissue oxygenation is significantly increased.</p></div>
<div class="block phk drugH1Div" id="F208234"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: 2 to 4 weeks with multiple doses </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Well absorbed </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic to multiple metabolites; undergoes extensive first-pass effect; Pentoxifylline undergoes reduction to metabolite I (active), and oxidation to form metabolite V (active) (Ward 1987); <b>Note: </b>Plasma concentrations of M-1 and M-V are 5 and 8 times greater, respectively, than pentoxifylline </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Parent drug: 24 to 48 minutes; Metabolites: 60 to 96 minutes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: 2 to 4 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (0% as unchanged, 50% to 80% as M-V metabolite, 20% as other metabolites); feces (&lt;4%)</p></div>
<div class="block phksp drugH1Div" id="F51159947"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Following a dose of 400 mg 3 times daily, AUC<sub>0-tss</sub> and C<sub>max</sub> of metabolite V (active) increased 2.4- and 2.1-fold, respectively, in patients with mild to moderate impairment, and 12.9- and 10.6-fold, respectively, in patients with severe impairment. Following a dose of 400 mg twice daily, AUC<sub>0-tss</sub> and C<sub>max</sub> of metabolite V (active) is only slightly smaller compared to 3-times-daily dosing in patients with mild to severe impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Following a single dose of pentoxifylline, the AUC increased 6.5-fold and the C<sub>max</sub> increased 7.5-fold in patients with mild to moderate hepatic impairment. The AUC and C<sub>max</sub> of active Metabolite I also increased 6.9- and 8.2-fold, respectively. Studies were not conducted in patients with severe hepatic failure.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Pentoxifylline: Increased AUC and decreased elimination rate (60 to 68 years of age).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F208240"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Trental</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Dilium | Dospan pento | Pentolab | Previscan | Tamixol</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Pentohexal | Pentomer | Pentoxi | Pentoximed | Vasonit</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Trental</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Vasolax</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Torental</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Pentillin | Pentophyllin | Pentoxifyllin | Pentoxypharm | Vasonit</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Pentalox | Pentox | Pentoxifilina | Pentral | Pentrat | Perental | Peripan | Trentofil | Vascer</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Trental</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Pentomer | Shu an ling</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Pentoxifilin | Pentoxifilina | Pentoxil | Perivax R | Vasonit</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo Pentoxifylline | Azupentat | Pentohexal | Pentomer | Pentoxifyllin al | Trental | Vasonit</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Agapurin | Azupentat | Claudicat | Durapental | Pentohexal | Pentox CT | Pentoxifyllin | Pentoxifyllin 1a pharma | Pentoxifyllin Acis | Pentoxifyllin al | Pentoxifyllin Basics | Pentoxy | Ralofekt | Rentylin | Trental</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Cebrekan | Pentoxifran</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Pentoxifilina | Perivax R | Pexal | Trental</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Agapurin | Dartelin | Flexital | Pentilin | Pentohexal | Pentoxifyllin ratiopharm | Ralofekt | Trental | Vasonit</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Normobral | Pental | Pentox | Pexal | Rebcoflex | Trental | Vasocare</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Nelorpin | Pentoxifilina | Pentoxifilina belmac | Pentoxifilina davur | Retimax</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Artal | Pentoxin | Trental</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Hatial | Pentoflux | Pentoxifylline gnr | Pentoxifylline Qualimed | Pentoxifylline rpg | Pentoxifylline teva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Neotren mr</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Cerator | Ipentol | Pentoxifyllin ratiopharm | Trenlin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Pentamon | Trental</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Agapurin | Angiopurin | Azupentat | Chinotal | Pentilin | Pentoxifyllin al | Pentoxifyllin-b | Pentoxyl | Pentoxyl ep</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Erypent | Erytral | Lentrin | Pentoxifilline | Reotal | Tioxad | Trenfyl | Trentox</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Trental</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Oxopurin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Erytal | Flexital | Kinetal | Pentovas | Rbflex | Trental</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Trental</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Pentoxine | Pentyllin | Trental</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Alatres l | Apophyllin | Atheriodin | Cerabion | Cerebcol | Cerevon | Coronafylline | Daiyamicron | Ebisanin | Elisdil | Hersaphin | Hobic chemiphar | Kizancohl kyowa hakko | Kizancohl merck hoei | Kurasute | Kuratotal | Licabrain | Metoloycin | Pantomarl | Pantomarl choseido | Papiror | Pendol | Penetrol | Pentafylan taiyo | Perantal l | Proxal | Rolymesn | Runter | Satellite | Sevstan | Sevstan daiko | Sevstan showa | Suneck | Techlon | Trenace | Trental | Unistarl | Vazofirin | Youretal mita | Youretal sankei | Yulcarl</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">CMG Pentoxifylline Sr | Harine sr | Pentowel sr | Pentoxin | Pentoxine | Perental | Trental</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Rivoxyn | Trental</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Arbiflex | Pentillin | Pentoxifyllin | Pentoxypharm | Ralofect | Rbflex | Trental | Vasonit</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Rentylin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Arbiflex | Dartelin | Pentillin | Pentomer | Pentoxifyllin | Pentoxypharm | Ralofect | Trental | Treptofilin | Vasonit</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Artelife | Capigard | Naxitren | Nemoplus | Oxilac | Pensiral | Pentoxifilin.gi se | Pentoxifilina | Profiben | Tecxifil | Vantoxil | Vantoxyl | Vasofyl | Zentocid</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Agapurin | Cerator | Trenlin | Trental</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Pentoxifyllin | Pentoxifylline pch | Trental</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Difusil | Durapental | Pentoxifilina | Perivax | Pexol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">C-vex | Toxipen | Vazofen</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Agapurin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Agapurin | Apo-pentox | Azupentat | Dartelin | Pentilin | Pentohexal | Polfilin | Polfilin prolongatum | Trental</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Pentoxil | Trental</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Claudicat | Pentoxifilina</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Artivena | Clem | Pentoxi mepha | Pentoxifilina chile | Pentoxifilina genfar | Pentoxifilina whelp</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Pentoxine | Trental</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Agapurin | Angiopent | Dartelin | Oxiflux | Oxyphyl | Pentilin | Vasonit</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Agapurin | Arbiflex | Flexital | Pentilin | Pentilin forte | Pentillin | Pentomer | Pentoxifyllin | Pentoxifylline fpo | Pentoxifylline sanofi | Pentoxifylline sz | Ralofect | Trental | Vasonit | Vazonit</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Trental</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Trenlin | Trental</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Dartelin | Pentilin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Agapurin | Pentilin | Pentoxifyllin al | Trental</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Agapurin | Cerator | Flexital | Herden | Penlol | Pentovas | Trepal</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Torral</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Penfixteva | Trental | Trentilin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cental | Ebisanin | Forflow | Fucon | Fylin | Fylin retard | Hexopal | Hobic | Ipentol | Pantomarl | Papiror | Penphylline | Pentathin | Pentol | Pentop | Pentosin | Pentoxifilline | Perilax | Recital | Sephylline | Shery | Sin Tong | Techlon | Throne | Trenfylline | Youretal</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Agapurin sr | Flexital | Pentillin | Pentomer | Pentoxifyllin | Pentoxipharm | Trentan | Vasonit</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cetofil | Conectal | Hemodinam | Oxifilin | Pentoxipharm | Raynal</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Agapurin | Pentoxifilina | Trental</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aspen Pentoxifylline | Dyna pentoxifylline sr | Dyna-pentoxifyllin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7996376">
<a name="7996376"></a>Aronoff SC, Quinn FJ, Carpenter LS, et al. Effects of Pentoxifylline on Sputum Neutrophil Elastase and Pulmonary Function in Patients With Cystic Fibrosis: Preliminary Observations. <i>J Pediatr</i>. 1994;125(6, pt 1):992-997.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/7996376/pubmed" id="7996376" target="_blank">7996376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7997416">
<a name="7997416"></a>Berman W Jr, Berman N, Pathak D, et al. Effects of Pentoxifylline (Trental®) on Blood Flow, Viscosity, and Oxygen Transport in Young Adults With Inoperable Cyanotic Congenital Heart Disease. <i>Pediatr Cardiol</i>. 1994;15(2):66-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/7997416/pubmed" id="7997416" target="_blank">7997416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24944359">
<a name="24944359"></a>Best BM, Burns JC, DeVincenzo J, et al. Pharmacokinetic and tolerability assessment of a pediatric oral formulation of pentoxifylline in kawasaki disease. <i>Curr Ther Res Clin Exp</i>. 2003;64(2):96-115.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/24944359/pubmed" id="24944359" target="_blank">24944359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-expert.dor">
<a name="expert.dor"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7957426">
<a name="7957426"></a>Furukawa S, Matsubara T, Umezawa Y, et al. Pentoxifylline and Intravenous Gamma Globulin Combination Therapy for Acute Kawasaki Disease. <i>Eur J Pediatr</i>. 1994;153(9):663-667.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/7957426/pubmed" id="7957426" target="_blank">7957426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Guyatt.1">
<a name="Guyatt.1"></a>Guyatt GH, Akl EA, Crowther M, et al. Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2)(suppl):7-47.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23235582">
<a name="23235582"></a>Jull AB, Arroll B, Parag V, Waters J. Pentoxifylline for treating venous leg ulcers. <i>Cochrane Database Syst Rev</i>. 2012;12:CD001733.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/23235582/pubmed" id="23235582" target="_blank">23235582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8319723">
<a name="8319723"></a>Lauterbach R. Pentoxifylline Treatment of Persistent Pulmonary Hypertension of Newborn. <i>Eur J Pediatr</i>. 1993;152(5):460. (I.V. use)<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/8319723/pubmed" id="8319723" target="_blank">8319723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7957428">
<a name="7957428"></a>Lauterbach R, Pawlik D, Tomaszczyk B, et al. Pentoxifylline Treatment of Sepsis of Premature Infants; Preliminary Clinical Observations. <i>Eur J Pediatr</i>. 1994;153(9):672-674. (I.V. use)<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/7957428/pubmed" id="7957428" target="_blank">7957428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22258970">
<a name="22258970"></a>Lu D, Song H, Li Y, et al. Pentoxifylline for Endometriosis. <i>Cochrane Database Syst Rev</i>. 2012;1:CD007677.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/22258970/pubmed" id="22258970" target="_blank">22258970</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3958924">
<a name="3958924"></a>Luke DR, Rocci ML Jr, Hoholick C. Inhibition of Pentoxifylline Clearance by Cimetidine. <i>J Pharm Sci</i>. 1986;75(2):155-157.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/3958924/pubmed" id="3958924" target="_blank">3958924</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8258882">
<a name="8258882"></a>MacDonald MJ, Shahidi NT, Allen DB, et al. Pentoxifylline in the Treatment of Children With New-Onset Type I Diabetes Mellitus. <i>JAMA</i>. 1994;271(1):27-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/8258882/pubmed" id="8258882" target="_blank">8258882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mauro.1">
<a name="Mauro.1"></a>Mauro VF, Mauro LS, Hageman JH. Alteration of Pentoxifylline Pharmacokinetics by Cimetidine. <i>Clin Pharmacol</i>. 1988;28(7):649-654.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28356445">
<a name="28356445"></a>McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. <i>Circulation</i>. 2017;135(17):e927-e999.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/28356445/pubmed" id="28356445" target="_blank">28356445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8929744">
<a name="8929744"></a>Nash MC, Wade AM. No evidence for use of pentoxifylline in acute Kawasaki disease. <i>Eur J Pediatr</i>. 1996;155(3):258.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/8929744/pubmed" id="8929744" target="_blank">8929744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24970885">
<a name="24970885"></a>Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. <i>J Am Soc Nephrol</i>. 2015;26(1):220-229. doi:10.1681/ASN.2014010012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/24970885/pubmed" id="24970885" target="_blank">24970885</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8826548">
<a name="8826548"></a>Paap CM, Simpson KS, Horton MW, et al. Multiple-dose pharmacokinetics of pentoxifylline and its metabolites during renal insufficiency. <i>Ann Pharmacother</i>. 1996;30(7-8):724-729.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/8826548/pubmed" id="8826548" target="_blank">8826548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oceanside.1">
<a name="Oceanside.1"></a>Pentoxifylline [prescribing information]. Bridgewater, NJ: Oceanside Pharmaceuticals; November 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAPharma.1">
<a name="AAPharma.1"></a>Pentoxifylline SR [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25936238">
<a name="25936238"></a>Practice Committee of the American Society for Reproductive Medicine. Diagnostic evaluation of the infertile female: a committee opinion. <i>Fertil Steril</i>. 2015;103(6):e44-e50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/25936238/pubmed" id="25936238" target="_blank">25936238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17199831">
<a name="17199831"></a>Robson MC, Cooper DM, Aslam R, et al. Guidelines for the Treatment of Venous Ulcers. <i>Wound Repair Regen</i>. 2006;14(6):649-662.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/17199831/pubmed" id="17199831" target="_blank">17199831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3428162">
<a name="3428162"></a>Silver MR, Kroboth PD. Pentoxifylline in end-stage renal disease. <i>Drug Intell Clin Pharm</i>. 1987;21(12):976-978. doi:10.1177/106002808702101209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/3428162/pubmed" id="3428162" target="_blank">3428162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Trental.1">
<a name="Trental.1"></a>Trental (pentoxifylline) [prescribing information]. Parsippany, NJ: Validus; January 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3308412">
<a name="3308412"></a>Ward A, Clissold SP. Pentoxifylline: A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Its Therapeutic Efficacy. <i>Drugs</i>. 1987;34(1):50-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/3308412/pubmed" id="3308412" target="_blank">3308412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3985069">
<a name="3985069"></a>Witter FR, Smith RV. The Excretion of Pentoxifylline and Its Metabolites Into Human Breast Milk. <i>Am J Obstet Gynecol</i>. 1985;151(8):1094-1097.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentoxifylline-pediatric-drug-information/abstract-text/3985069/pubmed" id="3985069" target="_blank">3985069</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12694 Version 235.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
